NO20060165L - Anvendelse av prionkonverteringsmodulerende midler - Google Patents

Anvendelse av prionkonverteringsmodulerende midler

Info

Publication number
NO20060165L
NO20060165L NO20060165A NO20060165A NO20060165L NO 20060165 L NO20060165 L NO 20060165L NO 20060165 A NO20060165 A NO 20060165A NO 20060165 A NO20060165 A NO 20060165A NO 20060165 L NO20060165 L NO 20060165L
Authority
NO
Norway
Prior art keywords
modulating agents
apolipoprotein
prion
prion conversion
conversion modulating
Prior art date
Application number
NO20060165A
Other languages
English (en)
Other versions
NO338179B1 (no
Inventor
Claudio Soto-Jara
Kinsey Maundrell
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of NO20060165L publication Critical patent/NO20060165L/no
Publication of NO338179B1 publication Critical patent/NO338179B1/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Neurology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)

Abstract

Anvendelse av Apolipoprotein B, Apolipoprotein E, fragmenter og hermere derav er tilveiebrakt for diagnose, deteksjon, prognose og terapeutisk anvendelse i prionsykdommer. Mer spesifikt tilveiebringer oppfmnelsen anvendelsen av Apolipoprotein B eller fragmenter derav til å modulere eller identifisere modulatorer av prion proteinreplikasjon som er implisert i patogenesen til overførbar spongioform encefalopati og andre prionsykdommer.
NO20060165A 2003-06-19 2006-01-11 Anvendelse av prionkonverteringsmodulerende midler NO338179B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03101795 2003-06-19
PCT/EP2004/051170 WO2004111652A1 (en) 2003-06-19 2004-06-18 Use of prion conversion modulating agents

Publications (2)

Publication Number Publication Date
NO20060165L true NO20060165L (no) 2006-01-11
NO338179B1 NO338179B1 (no) 2016-08-01

Family

ID=33547743

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060165A NO338179B1 (no) 2003-06-19 2006-01-11 Anvendelse av prionkonverteringsmodulerende midler

Country Status (9)

Country Link
US (2) US7598046B2 (no)
EP (1) EP1636592B1 (no)
JP (1) JP5133561B2 (no)
AU (2) AU2004248302B2 (no)
CA (1) CA2525517C (no)
ES (1) ES2401645T3 (no)
IL (1) IL172354A (no)
NO (1) NO338179B1 (no)
WO (1) WO2004111652A1 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009015091A1 (en) * 2007-07-20 2009-01-29 The Government of the United States of America as represented by the Secretary of the Detection of infectious prion protein by seeded conversion of recombinant prion protein
KR101483438B1 (ko) 2014-04-17 2015-01-16 한림대학교 산학협력단 극미량 병원성 프리온 단백질 검출방법 및 장치
DK3142386T3 (da) * 2015-09-08 2019-07-08 Oticon As Tætningsørestykke
US10434141B2 (en) 2016-05-31 2019-10-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
WO2019071355A1 (en) * 2017-10-13 2019-04-18 Uti Limited Partnership PRODUCTS AND METHODS RELATED TO MULTIPLE SCLEROSIS AS A DISORDER ASSOCIATED WITH MISUSE OF TRANSMISSIBLE PROTEINS
CN116133615A (zh) 2020-07-06 2023-05-16 美适牙冠有限责任公司 用于使用预制套筒-牙冠对进行牙冠修复的方法和装置

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5278059A (en) * 1985-12-04 1994-01-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaki Kenkyujo Polypeptide possessing cyclomaltodextrin glucanotransferase activity
US5134121A (en) 1988-03-28 1992-07-28 Regents Of The University Of California Nerve growth factor peptides
US5276059A (en) 1992-07-10 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of diseases associated with amyloid formation
TW457240B (en) 1995-04-20 2001-10-01 Janssen Pharmaceutica Nv Novel triazolones as apolipoprotein-B synthesis inhibitors
US6022683A (en) * 1996-12-16 2000-02-08 Nova Molecular Inc. Methods for assessing the prognosis of a patient with a neurodegenerative disease
US5948763A (en) 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
JP2001517198A (ja) * 1995-10-17 2001-10-02 ザ レジェンツ オブ ザ ユニバーシティー オブ カリフォルニア ニューロンリモデリングのアポリポ蛋白質ｅ４誘発性阻害を低減させる方法
JPH10239313A (ja) * 1997-02-27 1998-09-11 Dai Ichi Pure Chem Co Ltd ヘパリン親和性物質の測定方法
US6274603B1 (en) 1997-09-24 2001-08-14 Mcgill University Methods for increasing ApoE levels for the treatment of neurodegenerative disease
US6506880B2 (en) 1998-03-17 2003-01-14 The Uab Research Foundation Synthetic peptides that enhance atherogenic lipoprotein uptake and lower plasma cholesterol
US6211149B1 (en) 1998-08-03 2001-04-03 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors of formation of protease resistant prion protein
EP1133699A1 (en) * 1998-11-25 2001-09-19 Scios Inc. Prevention and treatment of amyloid-associated disorders
CA2325358C (en) 1999-11-10 2005-08-02 Pfizer Products Inc. 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b
IL139217A0 (en) 2000-03-13 2001-11-25 Applied Research Systems Monoclonal antibodies to the human ldl receptor, their production and use
US6335610B1 (en) * 2000-06-30 2002-01-01 Ford Global Technologies, Inc. Method and apparatus for determining the operational energy cost of a hybrid vehicle
SK287768B6 (sk) * 2000-07-07 2011-09-05 Laboratoires Serono Sa Spôsob diagnostiky alebo detekcie konformačného ochorenia, testovanie markera konformačného ochorenia, diagnostický kit a zariadenie na vykonávanie tohto spôsobu
DE10107083C2 (de) * 2001-02-13 2003-02-20 Abdulgabar Salama Pentosan Polysulfat als Ligand zum Nachweis von Prionen
DE20105791U1 (de) 2001-04-03 2002-08-14 MEKRA Lang GmbH & Co. KG, 90765 Fürth Spiegelanordnung für Kraftfahrzeuge
JP2002323662A (ja) * 2001-04-24 2002-11-08 Furukawa Electric Co Ltd:The 光フィルタの角度調整装置、角度調整方法及び光モジュール
US20040018554A1 (en) 2001-05-15 2004-01-29 Green Larry R. Methods and compositions for detection of bovine spongiform encephalopathy and variant creutzfeldt-jacob disease
KR100575944B1 (ko) 2001-06-28 2006-05-02 화이자 프로덕츠 인코포레이티드 미소체 트리글리세라이드 전달 단백질(ｍｔｐ) 및/또는아포지방단백질 ｂ(ａｐｏ ｂ)분비의 억제제로서의트리아미드-치환된 인돌, 벤조푸란 및 벤조티오펜
FR2827047B1 (fr) 2001-07-03 2003-09-26 Apoh Technollgies Sa Procede de separation et/ou detection et/ou identification et/ou quantification de proteines prions
US20050038035A1 (en) 2001-11-28 2005-02-17 Hisashi Takasugi Heterocyclic amide compounds as apolipoprotein b inhibitors
CA2514303C (en) 2002-11-13 2012-09-18 The Uab Research Foundation Synthetic single domain polypeptides mimicking apolipoprotein e and methods of use

Also Published As

Publication number Publication date
ES2401645T3 (es) 2013-04-23
CA2525517C (en) 2016-05-31
EP1636592B1 (en) 2012-12-19
US7598046B2 (en) 2009-10-06
CA2525517A1 (en) 2004-12-23
WO2004111652A1 (en) 2004-12-23
AU2009232094A1 (en) 2009-11-19
US20070020682A1 (en) 2007-01-25
AU2004248302B2 (en) 2009-07-30
US20090317380A1 (en) 2009-12-24
NO338179B1 (no) 2016-08-01
JP2007527504A (ja) 2007-09-27
AU2004248302A1 (en) 2004-12-23
JP5133561B2 (ja) 2013-01-30
EP1636592A1 (en) 2006-03-22
IL172354A (en) 2011-12-29

Similar Documents

Publication Publication Date Title
O'Loughlin et al. Basic concepts to novel therapies: a review of the diabetic foot
Devaux et al. ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome
Kim et al. Angioedema deaths in the United States, 1979–2010
BRPI0410348A (pt) compostos e usos dos mesmos na modulação de amilóide-beta
Yamaguchi et al. Effects of exercise level on biomarkers in a rat knee model of osteoarthritis
DE602004028590D1 (de) Gerät zur wiederherstellung der aortenklappe und dieses verwendende behandlungsverfahren
CO6260094A2 (es) Anticuerpos novedosos anti-alpha5beta1 y usos de los mismos
NO20083044L (no) Deteksjon av loselige adisponektinreseptorpeptider og anvendelse i diagnostikk og terapi
NO20064124L (no) Anvendelse av metformin og orlistat for behandling eller forebygging av fedme
NO20060165L (no) Anvendelse av prionkonverteringsmodulerende midler
NO20071018L (no) Kombinasjonsbehandling ved a anvende fusjonsproteiner omfattende GLP-1
AR047729A1 (es) Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe)
NO20065984L (no) Forbindelser og sammensetninger som PPAR modulatorer
MX2019005415A (es) Anticuerpos de il-6 y uso de los mismos.
BR0312102A (pt) sais de fosfato de carvedilol e/ou seus solvatos, composições correspondentes, e/ou métodos de tratamento
CY1113214T1 (el) Φαρμακευτικη συνθεση
EP1395285A4 (en) REAGENTS AND METHODS FOR MODULATING DKK-MEDIATED INTERACTIONS
NO20065983L (no) Forbindelser og sammensetninger som PPAR modulatorer
AR048135A1 (es) Uso de gen de amiloide a serico en el diagnostico y tratamiento del glaucoma y en la identificacion de agentes anti-glaucoma.
BRPI0515079A (pt) marcadores imobilizados e métodos de detecção de prions conformacionalmente alterados
DE602004014823D1 (de) Selektive norepinephrin-wiederaufnahmehemmer zur behandlung von hitzewallungen
Bruns et al. Quality of life after curative liver resection: a single center analysis
Doke et al. Time dependent decline of neutralizing antibody titers in COVID-19 patients from Pune, India and evidence of reinfection
BRPI0414365A (pt) composições, reagentes e kits para, e métodos de diagnosticar, monitorar e tratar obesidade e/ou diabetes
ATE514948T1 (de) In vitro verfahren zur diagnose von neurodegenerativen erkrankungen

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS